Related and Nonrelated Parties [Axis] Nonrelated Party [Member] Related Party [Member] Class of Stock [Axis] Series C-2 Preferred Stock [Member] Series D Preferred Stock [Member] Product and Service [Axis] Clinic Revenue [Member] Product [Member] Equity Components [Axis] Common Stock [Member] Preferred Stock [Member] Series C-1 Preferred Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Treasury Stock, Preferred [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Measurement Input Type [Axis] Measurement Input, Calibrated Discount Rate [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Convertible Notes and Interest [Member] Convertible Preferred Stock [Member] Warrant [Member] Business Combination [Axis] Family Beginnings PC [Member] Wood Violet Fertility LLC [Member] Intangible Asset, Finite-Lived, Class [Axis] Trade Names [Member] NAYA Therapeutics [Member] In Process Research and Development [Member] Legal Entity [Axis] Bloom INVO LLC [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Bloom Agreement [Member] Consolidated Entities [Axis] Georgia JV [Member] Alabama JV [Member] Debt Instrument [Axis] Alabama JV Note Receivable [Member] Investment, Name [Axis] HRCFG INVO, LLC [Member] Variable Interest Entity, Primary Beneficiary [Member] Variable Interest Entity, Not Primary Beneficiary [Member] NAYA Therapeutics Inc [Member] Asset Acquisition [Axis] Long-Lived Asset, Class [Axis] Manufacturing Equipment [Member] Medical Equipment [Member] Office Equipment [Member] Leasehold Improvements [Member] Asset Class [Axis] Fertility Clinic Services [Member] Goodwill [Member] Wisconsin Fertility Institute Acquisition [Member] Noncompete Agreements [Member] Assembled Workforce [Member] Related Party Demand Notes [Member] Related Party Convertible Notes [Member] Convertible Notes Payable [Member] Note Payable [Member] JAG Multi Investments LLC [Member] JAG Amendment [Member] JAG August Letter [Member] Title and Position [Axis] Chief Executive Officer [Member] Chief Financial Officer [Member] Revenue Loan and Security Agreement [Member] Board of Directors [Member] Series C-2 Convertible Preferred Stock [Member] Nonconsolidated Investees, Other [Member] Financial Instrument [Axis] 7% Secured Convertible Debenture [Member] Five Narrow Lane LP [Member] AIR Exercise and Reload Agreement [Member] Derivative Instrument [Axis] May 2025 Amended And Restated Debenture [Member] August 2025 Amended and Restated Debenture [Member] Pre-Funded Warrants [Member] Securities Purchase Agreement [Member] Common Warrants [Member] Sale of Stock [Axis] December 2025 Private Placement [Member] FNL Warrants [Member] Plan Name [Axis] 2019 Stock Incentive Plan [Member] Stock Incentive Plan [Member] Award Type [Axis] Share-Based Payment Arrangement [Member] Restricted Stock Units (RSUs) [Member] Prefunded Warrant [Member] Inducement Letter Agreement [Member] Class of Warrant or Right [Axis] New Warrant [Member] December 2025 Warrants [Member] Customer [Axis] No Customers [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Accounts Receivable [Member] Segments [Axis] Consolidation Items [Axis] Operating Segments [Member] Revenue From External Customers [Member] INVOcell Device [Member] Inter Segment Revenue [Member] Therapeutics [Member] J A G Notes [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS Current assets Cash Accounts receivable, net of allowances of $75,766 and $69,641 as of March 31, 2026 and December 31, 2025, respectively Inventory Prepaid expenses and other current assets Total current assets Property and equipment, net Lease right of use Intangible assets, net Goodwill Investment in NAYA Therapeutics Note receivable Total assets LIABILITIESAND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable and accrued liabilities Accrued compensation Notes payable Deferred revenue Lease liability, current portion Additional payments for acquisition, current portion Warrant liability Other current liabilities Total current liabilities Lease liability, net of current portion Liability for excess losses of equity method investee Notes payable – net of current portion Other liabilities, net of current portion Additional payments for acquisition, net of current portion Total liabilities Stockholders’ equity Preferred stock, value Common Stock, $.0001 par value; 50,000,000 shares authorized; 1,640,635 and 477,366 issued and outstanding as of March 31, 2026 and December 31, 2025, respectively Additional paid-in capital Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Accounts receivable, net of allowances Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Revenue: Total revenue Operating expenses Cost of services Cost of goods sold Selling, general and administrative expenses Depreciation and amortization Total operating expenses Loss from operations Other income (expense): Gain from equity method investment Loss on changes in fair value on warrant liability Interest expense Total other income (expense) Net loss from continuing operations Loss from discontinued operations Net loss Net loss from continuing operations per common share: Basic Diluted Net loss from discontinued operations per common share: Basic Diluted Net loss per common share: Basic Diluted Weighted average number of common shares outstanding: Basic Diluted Balance Balance, shares Mezzanine equity, shares Mezzanine equity, value Proceeds from the sale of common stock, net of fees and expenses Proceeds from the sale of common stock, net of fees and expenses, shares Preferred stock redemption, value Preferred stock redemption, shares Reclass of C-1 Preferred Stock from mezzanine equity, value Reclass of C-1 Preferred Stock from mezzanine equity, shares Warrant exercise - cashless Warrant exercise - cashless, shares Warrant exercise - prefunded Warrant exercise - prefunded, shares Stock options vested Dividends on preferred stock Dividends on preferred stock, shares Rounding for reverse split Rounding for reverse split, shares Net loss Common stock issued to service providers Common stock issued to service providers, shares Preferred stock conversion Preferred stock conversion, shares Warrant exercise, net of issuance costs of $575,016 Warrant exercise, shares Consideration in acquisition Consideration in acquisition, shares Balance Balance, shares Mezzanine equity, shares Mezzanine equity, value Statement of Stockholders' Equity [Abstract] Warrant exercise, net of issuance costs Statement of Cash Flows [Abstract] Cash flows used in operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Non-cash stock compensation issued for services Fair value of vested stock options Amortization of discount on notes payable Gain from equity method investment Changes in fair value on warrant liability Impairment loss Depreciation and amortization Changes in assets and liabilities: Accounts receivable Inventory Prepaid expenses and other current assets Accounts payable and accrued expenses Accrued compensation Deferred revenue Leasehold liability Accrued interest Net cash used in operating activities Cash used in investing activities: Payments to acquire property, plant, and equipment Payment for acquisitions Net cash used in investing activities Cash from financing activities: Proceeds from the sale of common stock, net of offering costs Proceeds from warrant exercise, net Payment deferred acquisition consideration Preferred stock redemption Principal payments on notes payable Net cash provided by financing activities Increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information: Interest Noncash activities: Accrued dividends on preferred stock Preferred stock redemption adjustment Preferred stock issued for acquisition Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Equity Awards Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Aggregate Available Rule 10b5-1 Arrangement Modified Non-Rule 10b5-1 Arrangement Modified Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Accounting Policies [Abstract] Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements [Abstract] Liquidity Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Business Combinations Variable Interest Entities Agreements And Transactions With Vies Agreements and Transactions with VIE’s Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations Inventory Disclosure [Abstract] Inventory Property, Plant, and Equipment [Abstract] Property and Equipment Intangible Asset, Goodwill and Other [Abstract] Intangible Assets and Goodwill Leases Leases Debt Disclosure [Abstract] Notes Payable Related Party Transactions [Abstract] Related Party Transactions Equity [Abstract] Stockholders’ Equity Equity-Based Compensation Warrants Warrants Segment Reporting [Abstract] Segment Reporting Income Tax Disclosure [Abstract] Income Taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Description of Business Basis of Presentation Business Segments Business Acquisitions Discontinued Operations Variable Interest Entities Equity Method Investments Use of Estimates Cash and Cash Equivalents Accounts Receivable, net Inventory Property and Equipment Long- Lived Assets Fair Value of Financial Instruments Derivatives Income Taxes Revenue Recognition Deferred Revenue Stock Based Compensation Loss Per Share Recently Adopted Accounting Pronouncements Accounting Pronouncements Not Yet Adopted Schedule of Accounts Receivable Schedule of Fair Value on Recurring Basis Schedule of Changes in Fair Value Schedule of Deferred Revenue Schedule of Earnings Per Share Basic and Diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Allocation of Purchase Price Schedule of Pro Forma Consolidated Results of Operations Schedule of Investments in Unconsolidated Variable Interest Entities Schedule of Earnings from Investments in Unconsolidated Variable Interest Entities Schedule of Financial Information of Investments in Unconsolidated Variable Interest Entities Summary of Transaction with Variable Interest Entities Summary of Balances with Variable Interest Entities Restructuring Cost [Table] Restructuring Cost and Reserve [Line Items] Schedule of Constituting Loss from Discontinued Operations Schedule of Inventory Schedule of Estimated Useful Lives of Property and Equipment Schedule of Property and Equipment Schedule of Finite-Lived Intangible Assets Schedule of Carrying Amount of Goodwill Schedule of Estimated Future Amortization Expense Schedule of Lease Components Schedule of Future Minimum Lease Payments Schedule of Notes Payable Schedule of Stock Options Activity Schedule of Share Based Payments Arrangements Options Exercised and Options Vested Schedule of Pre-funded Warrants Activity Schedule of Company’s Segments Including a Reconciliation to Income Before Taxes AccountingPoliciesTable [Table] AccountingPoliciesLineItem [Line Items] Number of Operating Segments Property plant and equipment estimated useful life Warrants measurement input Balance as of December 31, 2025 Provision Write-offs Recoveries Balance as of March 31, 2026 Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] Warrant liability Fair value, note receivable Fair value, warrant liability Fair value, note receivable Fair value, warrant liability Fair value, note receivable Fair value, warrant liability Fair value, note receivable Fair value, warrant liability Balance as of December 31, 2025 Additions to deferred revenue Revenue recognized from deferred revenue Balance as of March 31, 2026 Net loss (numerator) Basic weighted-average number of common shares outstanding (denominator) Diluted weighted-average number of common shares outstanding (denominator) Basic net loss per common share Diluted net loss per common share Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total Net loss from continuing operations Accumulated deficit Proceeds from Issuance of Warrants Business Combination [Table] Business Combination [Line Items] Cash Holdback Series D Preferred Business acquisition cost Assets and liabilities acquired: In process R&D Total assets and liabilities acquired Loss on disposition Series C-1 Preferred NTI Note Receivable NTI Series A Preferred Cash Other current assets AP & accrued liabilities Debt Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) Pro forma revenue Pro forma net loss Purchase price Number of shares issued on acquisition Payments made in cash Holdback funds Variable Interest Entity [Table] Variable Interest Entity [Line Items] Variable interest entity commitment contribution Variable interest entity units issued Hurdle amount Variable interest entity ownership, percentage Investments Notes receivable Noncontrolling interest Note receivable Reduced in notes receivable Principal balance Equity method investments Negative carrying value InvestmentsInUnconsolidatedVariableInterestEntitiesOfFinancialStatementsTable [Table] Percentage ownership Investment in unconsolidated variable interest entities Total earnings from unconsolidated VIEs Operating revenue Operating expenses Current assets Long-term assets Current liabilities Net assets SummaryOfTransactionWithVariableInterestEntitiesOfFinancialStatementsTable [Table] INVOcell revenue SummaryOfBalancesWithVariableInterestEntitiesOfFinancialStatementsTable [Table] Accounts receivable Notes payable and accrued interest Revenue Cost of revenue Selling, general, and administrative expenses Research and development expenses Impairment loss Depreciation and amortization Interest expense Loss on discontinued operations Common stock shares Preferred stock shares Common stock shares Interest rate Raw materials Finished goods Total inventory Property, Plant, and Equipment [Table] Property, Plant, and Equipment [Line Items] Estimated useful life Property, plant and equipment, gross Less: accumulated depreciation Total equipment, net Depreciation expense Tradename Noncompetition agreement Less: accumulated amortization Total intangible assets Impairment Effects on Earnings Per Share [Table] Impairment Effects on Earnings Per Share [Line Items] Goodwill Accumulated impairment losses Goodwill, net Impairment losses Goodwill written off related to divesture Goodwill acquired 2026 2027 2028 2029 2030 and beyond Total Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Line Items] Intangible Asset, Finite-Lived, Acquired Goodwill, Acquired During Period Intangible Asset, Finite-Lived, Useful Life Capitalized Contract Cost, Impairment Loss Amortization of intangible assets Schedule Of Lease Components Assets ROU assets – operating lease Total ROU assets Liabilities Current operating lease liability Long-term operating lease liability Total lease liabilities Schedule Of Future Minimum Lease Payments 2026 2027 2028 2029 2030 and beyond Total future minimum lease payments Less: Interest Total operating lease liabilities Weighted average remaining lease term Weighted average discount rate Operating lease payments Short-Term Debt [Table] Short-Term Debt [Line Items] Note payable, gross Total, net of discount Less current portion Long-term portion of notes payable Demand notes financing fee percentage Debt instrument, convertible, conversion price Cumulative interest rate Maturity date Principle balance Demand notes financing fee percentage Proceeds from issuance of demand notes Debt description Loss of fair value of warrants Payments to related party Exercise price per share Interest expense Interest repaid Balance debt Accured interest Proceeds from promissory notes Interest costs incurred Loans payable Interest rate description Equity investment investment Periodic repayment amount Reimburse amount Lender fees Amortization of Debt Discount (Premium) Related Party Transaction [Table] Related Party Transaction [Line Items] Principal amount Annual interest rate Warrants purchase of common stock Warrants exercises term Warrant exercise price Stock, Class of Stock [Table] Class of Stock [Line Items] Stockholders' Equity, Reverse Stock Split Preferred stock conversion price Beneficially percentage Preferred stock dividend percentage Conversion price percentage Debt conversion price percentage Conversion price Outstanding common stock percentage Principal amount Additional investment right exercised amount Number of shares Stock Issued During Period, Shares, Purchase of Assets Derivative Liability, Notional Amount Gain (Loss) on Extinguishment of Debt Additional investments cash Principal amount Stock Issued During Period, Shares, Acquisitions Stock Issued During Period, Value, Acquisitions Sale of stock Share price Debt description Number of pre-funded warrants Stock issued value Purchase and acquire shares Purchase and acquire shares, value Number of pre-funded warrants Proceeds from private placement Number of warrants Legal fees Common stock upon the exercise of prefunded warrants Number of common stock upon cashless exercise Proceeds from Issuance or Sale of Equity Common stock share issued upon conversion Number of shares issued services Number of shares, options outstanding Weighted average exercise price, outstanding Number of shares, options outstanding, granted Weighted average exercise price, options outstanding, granted Number of shares, options outstanding, exercised Weighted average exercise price, options outstanding, exercised Number of shares, options outstanding, canceled Weighted average exercise price, outstanding, canceled Number of shares, options outstanding Weighted average exercise price, outstanding Number of shares, options exercisable Weighted average exercise price, options exercisable Total intrinsic value of options exercised Total fair value of options vested Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Equity incentive plans description Number of shares of common stock available for issuance Expiration period Stock options, granted Weighted average remaining service period Number of restricted stock shares Schedule Of Warrants Activity Number of warrants, outstanding Weighted average exercise price, outstanding Number of warrants, granted Weighted average exercise price, granted Number of warrants, exercised Weighted average exercise price, exercised Number of warrants, canceled Weighted average exercise price, canceled Number of warrants, outstanding Weighted average exercise price, outstanding Class of Warrant or Right [Table] Number of pre-funded warrant, issued Weighted average exercise price, issued Number of pre-funded warrant, exercised Number of pre-funded warrant, canceled WarrantsTable [Table] WarrantsLineItems [Line Items] Common stock issued Proceeds from warrants Exercise Warrant issued Fair value of warrants Warrant exercise price increase Warrant exercise price decrease Warrants at issuance Net proceeds from warrants Loss on issuance of warrants Change in fair value of warrants Warrants held abeyance Segment Reporting [Table] Segment Reporting [Line Items]  Total revenue Elimination of intersegment revenue Total consolidated revenue Cost of revenue Sales and marketing General and administrative Segment profit (loss) Other income (loss) Other corporate expenses Loss before taxes Assets Research and development Impairment loss Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Table] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Line Items] Number of operating segments Number of reportable segments Concentartion risk percentage Income tax expense Income tax rate Notes, description Non-Rule 10b5-1 Arrangement Modified. Rule 10b5-1 Arrangement Modified Agreement and Transaction with Variable Interest Entities [Text Block] Summary of balances with variable interest entities [Table Text Block] Schedule of esimated useful lives of property and equiment [Table Text Block] Liability for excess losses of equity method investee. Manufacturing Equipment [Member] Medical Equipment [Member] Board of Directors [Member] Series C-2 Preferred Stock [Member] NAYA Therapeutics Inc [Member] Series C-2 Convertible Preferred Stock [Member] Debt instrument convertible threshold percentage of stock price. Preferred stock aggregate stated value. Additional investment right exercised. Five Narrow Lane LP [Member] AIR Exercise and Reload Agreement [Member] May 2025 Amended And Restated Debenture [Member] August 2025 Amended and Restated Debenture [Member] Pre-Funded Warrants [Member] Securities Purchase Agreement [Member] Common Warrants [Member] December 2025 Private Placement [Member] Cost of revenues. Net Loss From Continuing Operations Per Common Share [Abstract] Net Loss From Discontinued Operations Per Common Share [Abstract] Clinic Revenue [Member] Stock issued during period shares warrant exercised cashless and prefunded. Finite lived noncompetition agreement. Number of common stock upon cashless exercise. Fertility Clinic Services [Member] Therapeutics [Member] Prefunded Warrant [Member] Goodwill written off related to divesture. Wisconsin Fertility Institute Acquisition [Member] FNL Warrants [Member] Assembled Workforce [Member] Preferred stock redemption adjustment. NAYA Therapeutics [Member] Accrued dividends on preferred stock. 2019 Stock Incentive Plan [Member] Stock Incentive Plan [Member] Series C-1 Preferred Stock [Member] Right of use assets. Annual interest related party demand notes percentage. Related Party Demand Notes [Member] Warrants disclosure text block. Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price warrants. Share based compensation arrangement by share based payment award non options grants weighted average exercise price. Reclassification of temporary equity shares to permanent equity. Share based compensation arrangement by share based payment award non option equity instruments weighted average exercise price of warrants exercised. Share based compensation arrangements by share basedPayment award non options expired in period weighted average exercise price. Share based compensation arrangements by share basedPayment award non options canceled in period weighted average exercise price. Stock issued during period value warrants exercised cashless. Stock issued during period shares warrants exercised cashless. Stock issued during period value stock warrants exercised prefunded. Stock issued during period shares stock warrants exercised prefunded. Stock issued during period value reverse stock splits. Related Party Convertible Notes [Member] Note Payable [Member] JAG Multi Investments LLC [Member] Debt instrument financing fee percentage. JAG Amendment [Member] JAG August Letter [Member] Inducement Letter Agreement [Member] Stock issued during period value dividends on preferred. Stock issued during period shares dividends on preferred. Stock issued during period value stock warrants exercised. Stock issued during period shares warrant exercised. Revenue Loan and Security Agreement [Member] Debt instrument reimburse amount. Lender fees. 7% Secured Convertible Debenture [Member] Description of Business [Policy Text Block] New Warrant [Member] Warrant liability. Fair value remeasured. Change in fair value of warrants. Existing Warrants [Member] Change in valuation of note receivable. Change in valuation of warrant liability. December 2025 Warrants [Member] Loss on issuance of warrants. Measurement Input, Calibrated Discount Rate [Member] INVOcell Device [Member] Intersegment revenues. Other income loss. Segment assets. No Customers [Member] Convertible Notes and Interest [Member] Accounting Pronouncements Not Yet Adopted [Policy Text Block] Variable interest entity commitment contribution. Bloom INVO LLC [Member] Bloom Agreement [Member] Variable interest entity units issued. Hurdle amount. Georgia JV [Member] Alabama JV [Member] Alabama JV Note Receivable [Member] Negative carrying value. Schedule of Investments in Unconsolidated Variable Entities [Table Text Block] HRCFG INVO, LLC [Member] Investment in unconsolidated variable interest entities. Schedule of Earnings from Investments in Unconsolidated Variable Interest Entities [Table Text Block] Earning (Loss) from unconsolidated variable interest entities. Schedule of Financial Information of Investment in Unconsolidated Variable Interest Entities [Table Text Block] Revenue From External Customers [Member] Inter Segment Revenue [Member] Lessee operating lease liability payments due after year three. Family Beginnings PC [Member] Holdback funds. Business combination consideration transferred hold back. Business combination consideration transferred preferred stock. Wood Violet Fertility LLC [Member] Payments to acquire businesses series C one preferred stock. Asset acquisition consideration transferred from notes receivable. Payments to acquire businesses preferred stock. Disposal group including discontinued operation research and development expenses. Disposal group including discontinued operation impairment loss. Goodwill acquired. Common stock outstanding percentage. Reclassification to equity warrant liability. Reclassification to equity note receivable. Warrant exercise, net of issuance costs. Payment deferred acquisition consideration. J A G Notes [Member] Preferred stock issued for acquisition. Assets, Current Assets [Default Label] Liabilities, Current Liabilities [Default Label] Equity, Attributable to Parent Liabilities and Equity Costs and Expenses Operating Income (Loss) Interest Expense, Nonoperating Nonoperating Income (Expense) Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Shares, Outstanding Temporary Equity, Shares Outstanding Temporary Equity, Carrying Amount, Attributable to Parent Depreciation, Depletion and Amortization Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Employee Related Liabilities Increase (Decrease) in Deferred Revenue Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments to Acquire Property, Plant, and Equipment Payments to Acquire Investments Cash Provided by (Used in) Investing Activity, Including Discontinued Operation PaymentDeferredAcquisitionConsideration Payments for Repurchase of Redeemable Preferred Stock Repayments of Notes Payable Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Inventory Disclosure [Text Block] Lessee, Operating Leases [Text Block] WarrantsDisclosureTextBlock Discontinued Operations, Policy [Policy Text Block] Consolidation, Variable Interest Entity, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Property, Plant, and Equipment [Policy Text Block] Income Tax, Policy [Policy Text Block] WarrantLiability ReclassificationToEquityNoteReceivable ReclassificationToEquityWarrantLiability Deferred Revenue, Revenue Recognized Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Business Combination, Consideration Transferred, Tangible and Intangible Assets, Excluding Cash Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent Business Combination, Recognized Liability Assumed, Accounts Payable, Current Business Combination, Recognized Liability Assumed, Long-Term Debt, Current Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) Operating Costs and Expenses DisposalGroupIncludingDiscontinuedOperationImpairmentLoss Disposal Group, Including Discontinued Operation, Depreciation and Amortization Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization Intangible Asset, Finite-Lived, Accumulated Amortization Intangible Asset, Including Goodwill, after Accumulated Amortization Goodwill, Gross Goodwill, Impaired, Accumulated Impairment Loss Goodwill, Impairment Loss, Net of Tax Intangible Asset, Finite-Lived, after Accumulated Amortization RightOfUseAssets Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Notes Payable [Default Label] DebtInstrumentFinancingFeePercentage Interest Expense, Operating and Nonoperating Debt Conversion, Original Debt, Amount Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted average exercise price, beginning balance Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Cost of Revenue Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Other Expenses Operating Lease, Impairment Loss